Twist Bioscience Corporation TWST
Set alert
As of Nov 3, 11:18 AM ET
- YTD
- +330.99%
- 1 year
- +333.04%
- Open
- 130.35
- Prev close
- 129.04
- Mkt cap
- 9.06B
- Vol
- 737.76K
- Avg vol
- 2.32M
- EPS
- -2.23
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 130.22
- High
- 141.62
- Forward P/E
- -322.60
- Beta
- 2.22
- Short ratio
- 3.22
- Inst. own
- 117.41%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 153.11
- 200-d avg
- 89.02
- 1y target
- 168.25
YTD chart
Events in this range
- Feb 2, 2026Earnings: -0.5; estimate -0.48; surprise -4.17%
- May 4, 2026Earnings: -0.71; estimate -0.49; surprise -44.9%
- Aug 3, 2026Earnings: -0.56; estimate -0.50625; surprise -10.62%
- Sep 29, 2026Rating: Leerink Partners · Outperform → Outperform
- Oct 1, 2026Rating: Guggenheim · Buy → Buy
- Oct 7, 2026Rating: Barclays · Overweight → Overweight
- Oct 8, 2026Rating: Jefferies · — → Hold
- Oct 12, 2026Rating: Canaccord Genuity · Buy → Buy
- Oct 13, 2026Rating: TD Cowen · Buy → Buy
Signals (42)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 2026 | 1 day ago |
| SMA: Bearish | Oct 30, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 28, 2026 | 6 days ago |
| SMA: Bullish | Oct 27, 2026 | 1 week ago |
| SMA: Bearish | Oct 15, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| RSI: Overbought | Sep 24, 2026 | 1 month ago |
| RSI: Overbought | Sep 18, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| RSI: Overbought | Aug 10, 2026 | 2 months ago |
| RSI: Overbought | Aug 5, 2026 | 3 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 7, 2026 | 3 months ago |
| RSI: Overbought | Jun 24, 2026 | 4 months ago |
| RSI: Overbought | Jun 15, 2026 | 4 months ago |
| RSI: Overbought | Jun 3, 2026 | 5 months ago |
| MACD: Buy Signal | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
Newest 20 of 42.
Key statistics
- Market cap
- 8.56B
- Enterprise value
- 9.52B
- Trailing P/E
- 0.00
- Forward P/E
- -322.60
- PEG ratio
- 0.00
- Price / sales
- 19.81
- Price / book
- 18.14
- EPS (TTM)
- -2.23
- Beta
- 2.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -31.66%
- Revenue (TTM)
- 431.80M
- Revenue growth
- 23.20%
- Free cash flow
- -64.82M
- Total cash
- 166.84M
- Total debt
- 108.59M
- Return on equity
- -29.59%
- Shares outstanding
- 66.30M
- Short % of float
- 19.42%
- 50-day average
- 153.11
- 200-day average
- 89.02
Analyst view
Consensus: buy
- Target (low)
- 45.00
- Target (mean)
- 168.25
- Target (high)
- 215.00
- Strong buy2
- Buy7
- Hold3
- Sell1
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.203.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.38452 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | -0.50625 | -0.56 | -0.05 | -10.62% |
| May 4, 2026 | Mar 31, 2026 | -0.49 | -0.71 | -0.22 | -44.90% |
| Feb 2, 2026 | Dec 31, 2025 | -0.48 | -0.50 | -0.02 | -4.17% |
| Nov 14, 2025 | Sep 30, 2025 | -0.50 | -0.45 | +0.05 | +10.00% |
| Aug 4, 2025 | Jun 30, 2025 | -0.54 | -0.47 | +0.07 | +12.96% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | TD Cowen | main | Buy | Buy |
| Oct 12, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 8, 2026 | Jefferies | init | — | Hold |
| Oct 7, 2026 | Barclays | main | Overweight | Overweight |
| Oct 1, 2026 | Guggenheim | main | Buy | Buy |
| Sep 29, 2026 | Leerink Partners | main | Outperform | Outperform |
About Twist Bioscience Corporation
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- twistbioscience.com
News
- Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells
- Parnassus Mid Cap Growth Fund: Q3 2026 Performance Review
- Twist Bioscience Launches MRD Express with Rapid Turnaround Time
- 10 Health Care Stocks Whale Activity In Today’s Session
- Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies
- Allspring Emerging Growth Fund: Q3 2026 Top Contributors And Detractors
- TD Cowen Maintains Buy on Twist Bioscience, Raises Price Target to $190
- 10 Health Care Stocks With Whale Alerts In Today’s Session
- Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $205
- Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
Your note
Sign in to keep a note on TWST — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHAN NELSON C | Director | Stock Award(Grant) | Feb 4, 2026 | 33,251 |
| CHESS ROBERT BRUCE | Director | Sale | Aug 6, 2026 | 63,612 |
| CHO DENNIS | Officer | Sale | Oct 1, 2026 | 63,789 |
| CRANDELL KEITH L. | Director | Stock Award(Grant) | Feb 4, 2026 | 103,618 |
| FINN PATRICK JOHN | President | Sale | Oct 22, 2026 | 182,843 |
| GREEN PAULA | Officer | Sale | Oct 1, 2026 | 106,632 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.30% | 5,833,891 | 752.81M | Jun 29, 2026 |
| Artisan Partners Limited Partnership | 7.66% | 4,802,017 | 619.65M | Jun 29, 2026 |
| FMR, LLC | 7.50% | 4,703,044 | 606.88M | Jun 29, 2026 |
| ARK Investment Management, LLC | 7.26% | 4,549,803 | 587.11M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 5.80% | 3,634,652 | 469.02M | Jun 29, 2026 |
| State Street Corporation | 5.15% | 3,232,532 | 417.13M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.99% | 1,874,473 | 241.88M | Jun 29, 2026 |
| ARK ETF Trust-ARK Innovation ETF | 2.95% | 1,847,954 | 238.46M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.73% | 1,714,174 | 221.20M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.16% | 1,357,205 | 175.13M | Jun 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.92% | 1,201,502 | 155.04M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.88% | 1,177,281 | 151.92M | Sep 29, 2026 |